Log In
Sunday 20th May 2018

Kidney cancer drug rejected

10th July 2007

A charity says a ruling not to approve a kidney cancer drug for use in the NHS in Scotland is a ‚Äúdeath sentence‚Ä? to hundreds of patients.

The Scottish Medicines Consortium said the benefits of Sutent (Sunitinib) did not yet justify its high cost, even though the James Whale Fund said the drug is the most effective first-line treatment for advanced kidney cancer. Manufacturer Pfizer plans to resubmit a proposal to the SMC based on new evidence. A decision on the drug for use in England has yet to be made by the National Institute for Health and Clinical Excellence.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018